Synapse - Roni Shouval

Results (65)

A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2

Meeting Abstract

Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
Blood (2023)

Fulltext@MSK | Save

Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome

Meeting Abstract

Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
Blood (2023)

Fulltext@MSK | Save

18F-FDG PET/CT imaging biomarkers for car-T cell therapy outcomes in large-B-cell lymphoma

Meeting Abstract

Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M.; Luttwak, E.; more...
Blood (2023)

Fulltext@MSK | Save

Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells

Correspondence

Goldman, A.; Raschi, E.; Chapman, J.; Santomasso, B. D.; Pasquini, M. C.; Perales, M. A.; Shouval, R.
Blood (2023)

Fulltext@MSK | Save

Severe persistent cytopenias following CAR T-cell therapy in patients with large B-cell lymphoma

Meeting Abstract

De Lapuerta, M. C.; Shouval, R.; Tomas, A. A.; Flynn, J. R.; Devlin, S. M.; Batlevi, C. L.; Fein, J. A.; Giralt, S. A.; Lin, R. J.; Nath, K.; more...
Blood (2022)

Fulltext@MSK | Save

Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy

Meeting Abstract

Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
Blood (2022)

Fulltext@MSK | Save

Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium

Meeting Abstract

Scordo, M.; Flynn, J. R.; Devlin, S. M.; Gonen, M.; Parascondola, A.; Tomas, A. A.; Shouval, R.; Brower, J.; Porter, D. L.; Schuster, S. J.; more...
Blood (2022)

Fulltext@MSK | Save

Predictors and outcomes of immune effector cell associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T-cell therapy for aggressive B-cell non-Hodgkin lymphoma

Meeting Abstract

Patel, V.; Bhaskar, S.; Schuster, S. J.; Nastoupil, L. J.; Perales, M. A.; Shouval, R.; McGuirk, J. P.; Maziarz, R. T.; Chen, A.; Bachanova, V.; more...
Blood (2022)

Fulltext@MSK | Save

Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy

Meeting Abstract

Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
Blood (2022)

Fulltext@MSK | Save